Risperidone: a review of its use in the treatment of bipolar mania.

Article Details

Citation

Copy to clipboard

Fenton C, Scott LJ

Risperidone: a review of its use in the treatment of bipolar mania.

CNS Drugs. 2005;19(5):429-44.

PubMed ID

15907153 [ View in PubMed

]

Abstract

Risperidone (Risperdal) is an atypical antipsychotic with high affinity for 5-hydroxytryptamine (5-HT)2A, dopamine D2 and alpha1- and alpha2-adrenergic receptors. Risperidone is now approved in the UK and the US for use in bipolar mania. Risperidone < or =6 mg/day, as monotherapy or adjunctive therapy with first-line mood stabilisers, significantly improves moderate and severe bipolar mania and improves global functioning over 3 weeks. Improvements in Young Mania Rating Scale (YMRS) scores in double-blind trials were greater with risperidone than with placebo over 3 weeks, and similar to those with haloperidol over 3 and 12 weeks. Risperidone was reasonably well tolerated. Limited data are available on the combination of risperidone and carbamazepine. Risperidone, as monotherapy or combined therapy with lithium or valproate semisodium, is an effective treatment option in bipolar mania.

DrugBank Data that Cites this Article

Drugs

Risperidone

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Paliperidone	Alpha-1A adrenergic receptor	Protein	Humans	Unknown	Antagonist	Details
Paliperidone	Alpha-1B adrenergic receptor	Protein	Humans	Unknown	Antagonist	Details